Mission Boys and Girls Club First Major Blind Tennis Tournament

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

 Continuing its mission to provide exceptional medical care to patients across the Rio Grande Valley, DHR Health is pleased to welcome ophthalmologist Dr. Rachel Gelman to its team of healthcare providers.

As the demand for healthcare professionals continues to grow, introducing young students to the wide range of opportunities available in the medical field is more important than ever. From nurses and physicians to emergency responders, pharmacists and other essential healthcare workers, each plays a critical role in caring for patients and keeping communities healthy.

To help address the ongoing need for qualified workers in the Rio Grande Valley, South Texas Health System (STHS) has renewed its support of Valley Initiative for Development and Advancement (VIDA) through a $25,000 annual grant.